DEA Delays Production Of Marijuana Drug As Potential Treatment For MS And Huntington’s Disease

By Nina Zdinjak

MMJ International Holdings, in collaboration with a specialty pharmaceutical options company, has been production gelatin capsule medications dependent on compounds discovered in cannabis. The company will investigate these in clinical trials as likely treatment options for many sclerosis (MS) and Huntington’s disease (Hd).

The Providens, Rhode Island-dependent health care hashish investigate company had entered into a offer agreement with MMJ BioPharma Cultivation for them to provide pressure specific cannabis plants for further processing to most likely obtain Food and drug administration acceptance for its drug.

Picture by FilippoBacci/Getty Photographs

Issues With The DEA

MMJ BioPharma Cultivation applied for a DEA bulk manufacturing registration in 2018. The DEA software process is becoming delayed for a long time for explanations not known. The DEA delay has negatively impacted the development of the drug growth for patients struggling from MS and Hd.

Associated: Effectively Dealing with Numerous Sclerosis With Cannabis Oil And Minimal Aspect Consequences

“As MMJ Worldwide Holdings proceeds to progress to its scientific trials, these DEA delays are unparalleled,” stated Elio Mariani, PhD, MMJ’s govt dependable for research and development. “The statutory mandate of the DEA is safety and divergence and to facilitate the manufacturing of prescribed drugs to support individuals struggling from continual illness.”

Duane Boise, CEO of MMJ Global Holdings commented, “MMJ’s medical trials will present patient dosing, security, and efficacy knowledge to the Food and drug administration to prove that cannabis can deal with critical tremors, a neurological disorder that results in involuntary shaking. We firmly feel that our MMJ oral gel cap medicine, that contains the marijuana plant’s special pharmacological attributes, will be Fda-authorized as a secure and successful drug.”

Associated: Hashish For Tremors — What is Doing the job Proper Now And What is Not

MMJ International Holdings in 2019 was supplied DEA clearance to import hashish-primarily based products into the U.S. from Canada, a method that necessary the cooperation of various governmental agencies, such as the Food and drug administration and the U.S. Drug Enforcement Agency (DEA) and Wellness Canada.

To day, five accredited entities are currently stated on the DEA internet site but none are manufacturing a pharmaceutical these as MMJ International Holdings with filings with the Food and drug administration to carry out medical trials.

This write-up originally appeared on Benzinga and has been reposted with permission.